Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:MGTA

Magenta Therapeutics (MGTA) Stock Price, News & Analysis

Magenta Therapeutics logo

About Magenta Therapeutics Stock (NASDAQ:MGTA)

Advanced Chart

Key Stats

Today's Range
$0.68
$0.76
50-Day Range
$0.36
$0.76
52-Week Range
$0.32
$2.07
Volume
376,000 shs
Average Volume
848,835 shs
Market Capitalization
$42.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive MGTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Magenta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MGTA Stock News Headlines

Musk’s Project Colossus could mint millionaires
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.tc pixel
See More Headlines

MGTA Stock Analysis - Frequently Asked Questions

Magenta Therapeutics, Inc. (NASDAQ:MGTA) issued its quarterly earnings results on Thursday, November, 4th. The company reported ($0.15) earnings per share for the quarter, topping analysts' consensus estimates of ($0.17) by $0.02.

Magenta Therapeutics's stock split on Thursday, September 7th 2023.The 2-1 split was announced on Thursday, September 7th 2023. The newly minted shares were payable to shareholders after the market closes on Thursday, September 7th 2023. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

Magenta Therapeutics (MGTA) raised $100 million in an IPO on Thursday, June 21st 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Magenta Therapeutics investors own include TherapeuticsMD (TXMD), Sorrento Therapeutics (SRNE), NIO (NIO), Oncobiologics (OTLK), VBI Vaccines (VBIV), Corbus Pharmaceuticals (CRBP) and Dynavax Technologies (DVAX).

Company Calendar

Last Earnings
11/04/2021
Today
8/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:MGTA
CIK
1690585
Fax
N/A
Employees
67
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$76.46 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-70.88%
Return on Assets
-57.27%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
19.49
Quick Ratio
19.49

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.23 per share
Price / Book
0.57

Miscellaneous

Outstanding Shares
60,665,000
Free Float
51,456,000
Market Cap
$42.44 million
Optionable
Not Optionable
Beta
2.12

Social Links

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:MGTA) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners